Gene-editing has become one of the top investing buzzwords.
All as gene editing show progress in identifying and potentially curing diseases.
Even more impressive, according to Interesting Engineering, “researchers have already identified DNA errors as the cause of nearly 7,000 diseases. Thankfully, the growing world of genome editing could be the ‘spell-checker’ needed to detect and eventually fix these.”
In short, everyone should be excited about the potential here.
Editas Medicine (EDIT)
Editas Medicine is one of the top names in gene-editing with several trials. It’s working on treatments for ocular diseases such as Leber Congenital Amaurosis 10, Usher Syndrome, neurological diseases, B-Thalassemia, and cancer. It’s also working on EDIT-301 for sickle cell disease. In fact, Editas Medicine just filed a request with the US FDA to begin a Phase 1/2 study of EDIT-301 for sickle cell disease, which could be a winner given the success of preclinical data.
Global X Genomics and Biotechnology ETF (GNOM)
One of the best ways to diversify your gene editing portfolio is with an ETF such as the Global X Genomics and Biotechnology ETF.
According to Global X, it “seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.”
Better, at less than $26 a share, it offers diversification among top stocks like CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, PTC Therapeutics, Agilent Technologies, Sorrento Therapeutics, and dozens more. If you were to buy 100 shares of each stock in the ETF, it would cost you thousands of dollars. To buy 100 shares of GNOM costs $2,600.
Intellia Therapeutics (NTLA)
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.
This year, the company expects to submit Investigational New Drug applications to the US FDA. One is an IND for NTLA-5001 for the treatment of acute myeloid leukemia, mid-year. The other is an IND for NTLA-2002, as a possible treatment for hereditary angioedema in the second half of the new year. Approval could send the stock to higher highs.